Learning From Full Characterization of HIV Proviruses in People Receiving Long-Acting Cabotegravir/Rilpivirine With a History of Replication on the Antiretroviral Classes
Open Access
- 23 December 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (1) , ofae748
Abstract
Background: To better understand factors associated with virologic response, we retrospectively characterized the HIV proviruses of 7 people with HIV who received long-acting cabotegravir/rilpivirine (CAB/RPV-LA) and were selected according to the following criteria: virologic control achieved despite a history of viral replication on 1 or both corresponding antiretroviral classes (n = 6) and virologic failure (VF) after CAB/RPV-LA initiation (n = 1). Methods: Last available blood samples before the initiation of CAB/RPV-LA were analyzed retrospectively. Near full-length HIV DNA genome haplotypes were inferred from Nanopore sequencing by the in vivo Genome Diversity Analyzer to search for archived drug resistance mutations (DRMs) and evaluate the frequency and intactness of proviruses harboring DRMs. Results: Archived DRMs including G-to-A mutations were found in samples from 3 patients who maintained virologic control. Genomes harboring DRMs were majorly in minority variants (<20%) and were defective in all cases except for 1 participant. In this participant, intact genomes with the H221Y mutation on reverse transcriptase were detected representing 11 copies per 106 peripheral blood mononuclear cells. The other mutations observed in the participants of the study resulted most likely from hypermutations. The patient with VF presented archived mutations, all associated with defects. Other factors could explain this VF. Conclusions: Our findings highlight the difficulty in interpreting the clinical significance of DRMs when detected in proviral DNA and the need to filter out hypermutated sequences. Detected DRMs could be harbored by defective archived genomes unlikely to contribute to treatment failure.Keywords
Funding Information
- CHU Orléans
This publication has 35 references indexed in Scilit:
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 SuppressionNew England Journal of Medicine, 2020
- Defective HIV-1 proviruses produce viral proteinsProceedings of the National Academy of Sciences, 2020
- Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical ImplicationsClinical Microbiology Reviews, 2016
- Defective proviruses rapidly accumulate during acute HIV-1 infectionNature Medicine, 2016
- APOBEC3G-Induced Hypermutation of Human Immunodeficiency Virus Type-1 Is Typically a Discrete “All or Nothing” PhenomenonPLOS Genetics, 2012
- APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNARetrovirology, 2009
- LTR real‐time PCR for HIV‐1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01)Journal of Medical Virology, 2008
- HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypesAIDS, 2006
- Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcriptsNature, 2003
- Detecting hypermutations in viral sequences with an emphasis on G → A hypermutationBioinformatics, 2000